Roquefort Therapeutics Reports In-Vivo Safety for Midkine Oncology Antibodies
Roquefort Therapeutics (LSE: ROQ, OTCQB: ROQAF) (“Roquefort” or the “Company”) announces that two of its Midkine (MDK) antibody programs, ROQ-A1 and ROQ-A2, demonstrate in-vivo safety in the pre-clinical development programs. The pre-clinical programs were carried out by leading cancer research groups. ROQ-A1 and ROQ-A2 are two patented antibody medicines designed by Roquefort to target metastatic breast …
Roquefort Therapeutics Reports In-Vivo Safety for Midkine Oncology Antibodies Read More »